SE8803713D0 - Biologically active lipoprotein and its use - Google Patents

Biologically active lipoprotein and its use

Info

Publication number
SE8803713D0
SE8803713D0 SE19888803713A SE8803713A SE8803713D0 SE 8803713 D0 SE8803713 D0 SE 8803713D0 SE 19888803713 A SE19888803713 A SE 19888803713A SE 8803713 A SE8803713 A SE 8803713A SE 8803713 D0 SE8803713 D0 SE 8803713D0
Authority
SE
Sweden
Prior art keywords
lipoprotein
pharmaceutical composition
biologically active
patient
active lipoprotein
Prior art date
Application number
SE19888803713A
Other languages
English (en)
Swedish (sv)
Other versions
SE8803713A (de
Original Assignee
Kabigen Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20373667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE8803713(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of SE8803713A publication Critical patent/SE8803713A/xx
Priority to SE19888803713A priority Critical patent/SE8803713D0/xx
Application filed by Kabigen Ab filed Critical Kabigen Ab
Publication of SE8803713D0 publication Critical patent/SE8803713D0/xx
Priority to DE68904530T priority patent/DE68904530T3/de
Priority to EP89850346A priority patent/EP0368823B2/de
Priority to AT89850346T priority patent/ATE84799T1/de
Priority to JP1268838A priority patent/JP2963923B2/ja
Priority to AU42996/89A priority patent/AU623180B2/en
Priority to CA002000893A priority patent/CA2000893C/en
Priority to US07/423,346 priority patent/US5223481A/en
Priority to US08/064,382 priority patent/US5455227A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SE19888803713A 1988-10-18 1988-10-18 Biologically active lipoprotein and its use SE8803713D0 (sv)

Priority Applications (9)

Application Number Priority Date Filing Date Title
SE19888803713A SE8803713D0 (sv) 1988-10-18 1988-10-18 Biologically active lipoprotein and its use
DE68904530T DE68904530T3 (de) 1988-10-18 1989-10-11 Biologisch wirksames Lipoprotein und seine Verwendung.
EP89850346A EP0368823B2 (de) 1988-10-18 1989-10-11 Biologisch wirksames Lipoprotein und seine Verwendung
AT89850346T ATE84799T1 (de) 1988-10-18 1989-10-11 Biologisch wirksames lipoprotein und seine verwendung.
JP1268838A JP2963923B2 (ja) 1988-10-18 1989-10-16 生物学的に活性なリポタンパク質およびその使用
AU42996/89A AU623180B2 (en) 1988-10-18 1989-10-17 Biologicaly active lipoprotein and its use
CA002000893A CA2000893C (en) 1988-10-18 1989-10-17 Biologically active lipoprotein and its use
US07/423,346 US5223481A (en) 1988-10-18 1989-10-18 Biologically active lipoprotein and its use
US08/064,382 US5455227A (en) 1988-10-18 1993-05-21 Biologically active lipoprotein and its use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE19888803713A SE8803713D0 (sv) 1988-10-18 1988-10-18 Biologically active lipoprotein and its use

Publications (2)

Publication Number Publication Date
SE8803713A SE8803713A (de) 1988-10-18
SE8803713D0 true SE8803713D0 (sv) 1988-10-18

Family

ID=20373667

Family Applications (1)

Application Number Title Priority Date Filing Date
SE19888803713A SE8803713D0 (sv) 1988-10-18 1988-10-18 Biologically active lipoprotein and its use

Country Status (8)

Country Link
US (2) US5223481A (de)
EP (1) EP0368823B2 (de)
JP (1) JP2963923B2 (de)
AT (1) ATE84799T1 (de)
AU (1) AU623180B2 (de)
CA (1) CA2000893C (de)
DE (1) DE68904530T3 (de)
SE (1) SE8803713D0 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3888823T2 (de) * 1987-09-01 1994-08-11 Teijin Ltd Verfahren zum testen einer wirksamen substanz die sich auf der oberfläche menschlicher lungen befindet.
SE8803713D0 (sv) * 1988-10-18 1988-10-18 Kabigen Ab Biologically active lipoprotein and its use
WO1991000871A1 (en) * 1989-07-11 1991-01-24 Genentech, Inc. Surfactant compositions and methods
CA2063273C (en) * 1989-07-11 2002-09-24 Bradley J. Benson Surfactant compositions and methods
DE69125750D1 (de) * 1990-05-21 1997-05-28 Abbott Lab Fettsäure-Oberflächenaktives-Lungenprotein Konjate
US5258496A (en) * 1990-07-10 1993-11-02 Scios Nova Inc. Isolation and purification of lung surfactant protein
US5272252A (en) * 1991-11-04 1993-12-21 Merrell Dow Pharmaceuticals Inc. Synthetic lung surfactant having antioxidant properties
JP3961029B2 (ja) * 1992-06-24 2007-08-15 博 木戸 インフルエンザウィルス感染防止剤
ES2189825T3 (es) * 1993-12-08 2003-07-16 Mitsubishi Pharma Corp Nuevo peptido sintetico, tensioactivo pulmonar que lo contiene y remedio para el sindrome de malestar respiratorio.
DE4418936A1 (de) * 1994-05-31 1996-02-08 Byk Gulden Lomberg Chem Fab Polypeptid
FR2739860B1 (fr) * 1995-10-17 1998-01-02 Coletica Complexes amphiphiles, procede pour leur preparation et compositions en renfermant
DE69733947T2 (de) * 1996-05-15 2006-06-14 Altana Pharma Ag Verfahren zur trennung und bestimmung von hydrophoben proteinen durch dünnschichtchromatographie
US6476191B1 (en) 1999-02-05 2002-11-05 Mixture Sciences, Inc. Volatilizable solid phase supports for compound synthesis
IT1308180B1 (it) 1999-02-12 2001-12-07 Chiesi Farma Spa Peptidi sintetici aventi la capacita' di diminuire la tensionesuperficiale e loro impiego nella preparazione di un surfattante
AU6083899A (en) 1999-09-16 2001-04-17 Aventis Behring Gmbh Combination of c1-inh and lung surfactant for the treatment of respiratory disorders
ATE468131T1 (de) 2001-10-11 2010-06-15 Nycomed Gmbh Neue verwendung von lungensurfactant
EP1781323B1 (de) 2004-08-06 2010-02-17 Nycomed GmbH Zusammensetzung aus einem pulmonalen surfactant und einem von tnf stammenden peptid
US7464012B2 (en) * 2004-12-10 2008-12-09 L'air Liquide, Societe Anonyme A Directoire Et Conseil De Surveillance Pour L'etude Et L'exploitation Des Procedes Georges Claude Simplified process simulator
US7582312B2 (en) 2004-11-15 2009-09-01 Discovery Laboratories, Inc. Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof
AU2006203978B2 (en) 2005-01-06 2011-11-03 Discovery Laboratories, Inc. Surfactant treatment regimen for treating or preventing bronchopulmonary dysplasia
JP2007309695A (ja) * 2006-05-16 2007-11-29 Univ Of Tokyo 質量分析のための脂質修飾ペプチドの抽出方法
AU2007297691B2 (en) * 2006-09-19 2013-12-19 Discovery Laboratories, Inc. Pulmonary surfactant formulations and methods for promoting mucus clearance
US7951781B2 (en) 2006-11-02 2011-05-31 University Of Iowa Research Foundation Methods and compositions related to PLUNC surfactant polypeptides
JP5554702B2 (ja) * 2007-06-05 2014-07-23 パカ パルモナリー ファーマシューティカルズ， インコーポレイテッド 薬剤を肺に送達するための方法および組成物
CA2744940A1 (en) 2008-12-10 2010-06-17 Paka Pulmonary Pharmaceuticals, Inc. Methods and compositions for delivery of medicaments to the lungs
WO2013188016A2 (en) 2012-05-04 2013-12-19 Discovery Laboratories, Inc. Surfactant therapy for exposure to ionizing radiation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4234475A (en) * 1975-08-15 1980-11-18 The Gillette Company Reacting protein with organic acid
DE2925942A1 (de) * 1979-06-27 1981-01-22 Bayer Ag Disazokupferkomplex-reaktivfarbstoffe
US4406833A (en) * 1982-06-04 1983-09-27 Fats And Proteins Research Foundation, Inc. Surfactants derived from fatty acid esters and proteinaceous material
US4659805A (en) * 1984-12-11 1987-04-21 California Biotechnology, Inc. Recombinant alveolar surfactant protein
US4933280A (en) * 1984-12-11 1990-06-12 California Biotechnology Inc. Recombinant DNA sequence encoding Alveolar Surfactant Protein
US4882422A (en) * 1985-10-24 1989-11-21 Genetics Institute, Inc. Pulmonary surfactant proteins
US4918161A (en) * 1985-09-26 1990-04-17 Genetics Institute, Inc. Low molecular weight pulmonary surfactant proteins
JPS63503222A (ja) * 1986-05-06 1988-11-24 サイオス　ノバ　インコーポレイテッド 肺の疎水性界面活性物質に結合した分子量６，０００ダルトンのタンパク質及びその多量体
US5013720A (en) * 1986-05-06 1991-05-07 Abbott Laboratories SAP-6-Val proteins and methods
EP0290516A4 (de) * 1986-10-24 1989-11-14 Jeffrey A Whitsett Proteine, die mit oberflächenwirksamen hydrophoben lungenwirkstoffen verbunden sind.
JPH01501282A (ja) * 1986-12-08 1989-05-11 ホイツトセツト，ジエフリー　エイ． 肺胞疎水性界面活性物質関連タンパク質
IT1203873B (it) * 1987-04-08 1989-02-23 Chiesi Farma Spa Composizioni farmaceutiche che lo surfattante polmonare naturale, contengono. metodo di preparazione e
WO1989000167A1 (en) * 1987-07-01 1989-01-12 Kabigen Ab Proteins and protein compositions and their use
US4861756A (en) * 1988-03-08 1989-08-29 Merrell Dow Pharmaceuticals Inc. Synthetic pulmonary surfactant
SE8803713D0 (sv) * 1988-10-18 1988-10-18 Kabigen Ab Biologically active lipoprotein and its use
US4993280A (en) * 1989-07-17 1991-02-19 Motorola, Inc. Rotational control assembly

Also Published As

Publication number Publication date
JP2963923B2 (ja) 1999-10-18
ATE84799T1 (de) 1993-02-15
SE8803713A (de) 1988-10-18
DE68904530D1 (de) 1993-03-04
CA2000893C (en) 2000-08-08
AU623180B2 (en) 1992-05-07
AU4299689A (en) 1990-04-26
EP0368823B2 (de) 1998-12-23
DE68904530T2 (de) 1993-07-29
EP0368823A3 (en) 1990-05-23
US5455227A (en) 1995-10-03
EP0368823A2 (de) 1990-05-16
EP0368823B1 (de) 1993-01-20
CA2000893A1 (en) 1990-04-18
JPH02145599A (ja) 1990-06-05
DE68904530T3 (de) 1999-07-08
US5223481A (en) 1993-06-29

Similar Documents

Publication Publication Date Title
SE8803713D0 (sv) Biologically active lipoprotein and its use
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
DK1201241T3 (da) Sammensætninger indeholdende capsaicin eller capsaicinanaloge og et bedøvelsesmiddel
ATE55908T1 (de) Grenzflaechenaktives mittel und dieses enthaltende arzneimittel zur verwendung bei der behandlung des atemnotsyndroms.
ATE115147T1 (de) Rekombinantes alveolares oberflächenaktives protein.
DK0699068T3 (da) Reduktion af liposominducerede fysiologiske bivirkninger
ATE143260T1 (de) Verwendung von (s)-isofluran und (s)-desfluran zur anästhesie sowie entsprechende arzneimittelzubereitungen
DE69615984D1 (de) Verwendung von Ursolsäure zur Herstellung eines Arzneimittels zur Unterdrückung von Metastasen
DE68912589D1 (de) Mittel zur verbesserung des fettabbaus und verfahren zur verwendung.
ATE88633T1 (de) Verwendung von bestimmten calcium-citrate-malaten zur herstellung einer pharmazeutischen zubereitung fuer die behandlung von osteoporose.
DE69326122D1 (de) Verwendung von wachstumsfaktor igf-ii zur beahandlung von gastrointestinalen störungen
DE69021257T2 (de) Verwendung von IFN-gamma zur Herstellung einer pharmazeutischen Zusammensetzung für die Behandlung von ATL.
FI915654A0 (fi) Somatotropiner med alterneringar i alfahelixregionen 1 och kombinationer med andra mutationer.
ES2092969A1 (es) Surfactante pulmonar natural de origen porcino.
NZ222867A (en) Use of epidermal growth factor to enhance iron uptake into the bloodstream and pharmaceutical compositions
ATE40795T1 (de) Verwendung eines zerebral und peripher wirkenden antihypoxidotikums.
Brouqui et al. Treatment of osteo-arthritis with ofloxacin. Preliminary report.